Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC assesses boceprevir and telaprevir for chronic hepatitis C

Published: 10 November 2011
New research into hepatitis C

SHTAC is assessing the clinical-effectiveness and cost-effectiveness of boceprevir and telaprevir to treat chronic hepatitis C. The assessments will be used to inform the single technology appraisals undertaken by the National Institute for Health and Clinical Excellence (NICE).

SHTAC is producing two Evidence Review Group (ERG) reports for the National Institute for Health and Clinical Excellence (NICE) to inform their single technology appraisals of boceprevir and telaprevir for hepatitis C. Both drugs are from a class of drugs known as ‘protease inhibitors', and have been studied in the treatment of a sub-group of patients who have harder to treat hepatitis C genotype 1. NICE's guidance on boceprevir is expected in May 2012 and guidance on telaprevir in June 2012. The ERG reports are expected to be available on the Health Technology Assessment programme website in January 2012.

For more information on SHTAC's previous research into hepatitis please visit our research page.

Privacy Settings